Waterjet surgery for BPH under the microscope: 3,000-Patient registry launches
NCT ID NCT07430423
First seen Jun 27, 2026 · Last updated Jul 08, 2026 · Updated 2 times
Summary
This registry will follow 3,000 men with benign prostatic hyperplasia (BPH) who undergo Aquablation, a waterjet-based procedure to remove excess prostate tissue. Researchers will collect data from medical records to evaluate how well the procedure improves urinary symptoms and its safety. No extra tests or visits are required beyond standard care.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Aquablation (waterjet ablation) procedure
- What this could lead to
- If successful, this registry could provide real-world evidence on how well Aquablation works for BPH and help identify which patients benefit most.
- What could go wrong
- This is an observational registry, not a controlled trial, so it cannot prove cause and effect. Results may be influenced by differences in patient care or data quality.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 3,000 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Aug 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2036
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with benign prostatic hyperplasia undergoing Aquablation of the prostate
- Ages
-
18 years and older
- Sex
-
Male participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Male sex * ≥18 years of age * Diagnosis of benign prostatic hyperplasia * Scheduled to undergo or have already undergone Aquablation as part of routine clinical care or any ongoing clinical trials * Aquablation performed with ultrasound guided, robotic assisted waterjet. Newer methods and instrumentation continue to be developed to ablate tissue, and these energy sources can be entered into the registry as clinical use begins. Exclusion Criteria: * Under 18 Years of age.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Benign prostatic hyperplasia (BPH) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
The University of Chicago
Chicago, Illinois, 60637, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a tiny spring implant replace daily pills for enlarged prostate?
- Steam and scans: a sharper way to shrink an enlarged prostate?
- New prostate surgery technique aims to shorten operation time
- Laser vs bipolar: which surgery best tames an oversized prostate?
- Banana flower extract tested to ward off prostate trouble
- New probe zaps away prostate troubles in landmark trial